Literature DB >> 9423803

Erythropoietin administration increases production and reactivity of platelets in dogs.

R F Wolf1, J Peng, P Friese, L S Gilmore, S A Burstein, G L Dale.   

Abstract

Administration of erythropoietin (EPO) to adult dogs resulted in a dramatic increase in the number of thiazole orange-positive (TO+) platelets, also referred to as reticulated platelets. Pre-treatment level of TO+ platelets was 6.2 +/- 0.5% (mean +/- 1 SE: n = 5); following day 5 of treatment with 500 U EPO/kg/day, the percentage of TO+ platelets peaked at 16.8 +/- 2.3% (n = 5; p <0.02). After cessation of the hormone, the number of TO+ platelets fell rapidly to below starting levels. Unexpectedly, there was a significant decline in total platelet count during EPO administration despite an increased level of TO+ platelets. To assess platelet reactivity, total platelets and TO+ platelets from EPO-treated dogs were analyzed for thrombin-responsiveness as quantitated by P-selectin expression on the cell surface; reactivity was expressed as a thrombin EC50, the thrombin concentration required to activate 50% of platelets. Both total and TO+ platelets were hyperreactive during EPO treatment when compared either to pre-treatment values or to control animals. Thrombin EC50 values for total and TO+ platelets on day 5 fell to 66.5 +/- 5.4% (mean +/- 1 SE; n = 5; p <0.02) and 62.2 +/- 8.7% (n = 5; p <0.025), respectively, of pre-treatment levels. These data indicate that EPO not only promotes the synthesis of increased numbers of TO+ platelets in the dog but that these newly produced platelets are hyperreactive when compared to TO+ platelets from control animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9423803

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  Erythropoietin neuroprotection with traumatic brain injury.

Authors:  Lucido L Ponce; Jovany Cruz Navarro; Osama Ahmed; Claudia S Robertson
Journal:  Pathophysiology       Date:  2012-03-14

2.  Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for Neuroprotection against Ischemic Neuronal Injury.

Authors:  Feng Zhang; Juan Xing; Anthony Kian-Fong Liou; Suping Wang; Yu Gan; Yumin Luo; Xuming Ji; R Anne Stetler; Jun Chen; Guodong Cao
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 3.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

4.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

5.  Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.

Authors:  Ismayil Ahmet; Hyun-Jin Tae; Michael Brines; Anthony Cerami; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2013-04-12       Impact factor: 4.030

6.  Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats.

Authors:  Yanhui Zhou; Bin Sun; Junhong Guo; Guohong Zhou
Journal:  Biomed Rep       Date:  2020-08-25

7.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

Authors:  Serhat Erbayraktar; Giovanni Grasso; Alessandra Sfacteria; Qiao-wen Xie; Thomas Coleman; Mads Kreilgaard; Lars Torup; Thomas Sager; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Pietro Ghezzi; Pia Villa; Maddalena Fratelli; Simona Casagrande; Marcel Leist; Lone Helboe; Jens Gerwein; Søren Christensen; Marie Aavang Geist; Lars Østergaard Pedersen; Carla Cerami-Hand; Jean-Paul Wuerth; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

8.  Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.

Authors:  Stefan Bohr; Suraj J Patel; Keyue Shen; Antonia G Vitalo; Michael Brines; Anthony Cerami; Francois Berthiaume; Martin L Yarmush
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

9.  Effects of high altitude and sea level on mean platelet volume and platelet count in patients with acute coronary syndrome.

Authors:  Ahmet Taha Alper; Serdar Sevimli; Hakan Hasdemir; Zekeriya Nurkalem; Tolga Sinan Güvenç; Ahmet Akyol; Nazmiye Cakmak; Gündüz Durmuş; Kadir Gürkan
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

10.  Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.

Authors:  Rudy Chang; Abrar Al Maghribi; Victoria Vanderpoel; Vitaly Vasilevko; David H Cribbs; Ruben Boado; William M Pardridge; Rachita K Sumbria
Journal:  Mol Pharm       Date:  2018-10-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.